Litcius/Paper detail

COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders

Hannah Kaminski, Mickael Gigan, Agathe Vermorel, Manon Charrier, Laura Guirle, Frédéric Jambon, Arthur Lacapère, Coline Ménard, Karine Moreau, Martine Neau‐Cransac, Marine Novion, Frederique Pribat, Benjamin Taton, Sébastien Borde, Laure Burguet, C Martinez, M. Jasiek, Pauline D’Halluin, Marie‐Edith Lafon, Pierre Merville, Lionel Couzi

2022Kidney International51 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakKidney transplantVirologyRenal transplantKidney transplantationImmunologyInternal medicineKidneyInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRenal Transplantation Outcomes and Treatments
COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders | Litcius